Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

New drug approvals and strong pipeline progress are likely to help ... it through our "Recent Price Strength" screen. Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a pinnacle of $51.88. With a market capitalization of $4.12 billion and an ...

Looking beyond the current success of Ohtuvayre's launch, Truist Securities is also anticipating updates throughout 2025 regarding Verona Pharma's pipeline. These updates are expected to include ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing the rate of exacerbations over a 24-week period. The ...